Dr. Spellberg is chief medical officer at the Los Angeles County-University of Southern California (LAC+USC) Medical Center. He is also a professor of clinical medicine and associate dean for clinical affairs at the Keck School of Medicine at USC. He received his BA in molecular cell biology-immunology from UC-Berkeley, attended medical school at UCLA, and completed residency training and his infectious diseases fellowship at Harbor-UCLA Medical Center.
Dr. Spellberg has worked extensively with IDSA to attempt to bring attention to the problems of increasing drug resistance and decreasing new antibiotics. As a member and then co-chair of the IDSA’s Antimicrobial Availability Task Force, he first-authored numerous IDSA position papers and review articles relating to public policy of antibiotic resistance and antibiotic development.
Recently he has provided leadership to the global ID community on the themes of ‘Shorter is better’, that ‘Oral is the new IV’, and the development of WikiGuidelines for Infectious Diseases.
Presentation by Dr Brad Spellberg, Chief Medical Officer at the Los Angeles County-University of Southern California (LAC+USC) Medical Center.
On this day last year, the SNAP trial started recruitment. 12 months on, more than 450 participants have joined the study, already making it the second largest clinical trial for Staphylococcus aureus bloodstream infections in the world.
Staphylococcus aureus can cause sepsis, among other infections, and sends more than 450 Australian babies, children and teenagers to hospital annually, according to Telethon Kids Institute.
